Hypertension Crisis in Singapore: A Growing Public Health Challenge

Singapore faces a significant burden from hypertension, with the National Population Health Survey 2024 revealing that 33.8% of residents aged 18 to 74 years have high blood pressure. This figure has remained stable over recent years but underscores the need for innovative management strategies in primary care, where most cases are handled. As the 'silent killer', uncontrolled hypertension contributes to cardiovascular diseases, stroke, and kidney failure, straining Singapore's healthcare system. Researchers at Duke-NUS Medical School, a premier graduate institution in partnership with the National University of Singapore (NUS), and SingHealth are at the forefront, leveraging home blood pressure monitoring (HBPM) to empower patients and clinicians alike.

Home blood pressure monitoring involves patients measuring their blood pressure (BP) at home using validated devices, providing more reliable data than single clinic readings. Singapore's primary care guidelines endorse HBPM with a diagnostic threshold of 135/85 mmHg, emphasizing its role in confirming diagnoses and tracking treatment efficacy. Yet, implementation challenges persist, highlighting the urgency of research from institutions like Duke-NUS.

Understanding Clinical Decision Support Systems for Hypertension

Clinical Decision Support Systems (CDSS) are tools—often software-based—that analyze patient data to offer tailored recommendations, such as medication adjustments or lifestyle advice. In hypertension management, CDSS integrated with HBPM can process self-measured readings to guide primary care physicians (PCPs). A landmark scoping review by Duke-NUS and SingHealth researchers, published in October 2025 in the Journal of Medical Internet Research, synthesized evidence on these systems.

This review, led by Dr. Aminath Shiwaza Moosa from SingHealth Polyclinics, Dr. Jun Jie Benjamin Seng from SingHealth Duke-NUS Family Medicine Academic Clinical Programme, and Prof. Chirk Jenn Ng, examined 33 studies (29 unique) from 2000 to 2023. It reveals CDSS promise but identifies critical gaps, positioning Duke-NUS as a leader in translational research for Singapore's healthcare.

Key Findings from the Duke-NUS-SingHealth Scoping Review

The review found that 86% of studies reported improved BP control, and 84% noted antihypertensive medication adjustments when using CDSS with HBPM. Computerized CDSS (64% of studies) dominated, featuring rule-based algorithms (100%), automatic data upload (81%), and alerts for abnormal readings (90%). Noncomputerized systems (36%) relied on manual processes like paper diaries but still achieved positive outcomes in 72% for BP control.

• Algorithms primarily drew from expert consensus (61%) rather than formal guidelines (27%).
• Patient education was universal in noncomputerized systems but only in 57% of computerized ones.
• Clinician training was rare (5-25%).

Users praised convenience and remote monitoring but cited usability issues and data access barriers. These insights are vital for Singapore, where polyclinics manage most hypertension cases.

Challenges in Primary Care: Insights from Duke-NUS Research

A complementary 2024 qualitative study by the same team explored PCP challenges with HBPM in Singapore polyclinics. Interviews with 17 physicians revealed five themes: variable patient monitoring practices, inconsistent documentation, reliance on patients for records, laborious EMR transfer, and interpretation difficulties with fluctuating readings.

PCPs noted patients often forget devices or records, use improper techniques, or avoid monitoring due to motivation lacks. Without seamless integration, manual entry burdens workflows. This underscores CDSS potential to standardize processes, a focus of Duke-NUS's research training for future physicians.

SingHypertension Trial: Proven Multi-Pronged Approach

Duke-NUS and SingHealth's SingHypertension cluster-randomized trial (2020-2022) tested a scalable intervention across polyclinics, achieving superior BP control at S$20 per patient annually. Involving over 900 patients, it combined nurse counseling, fewer pills via risk-based prescribing, and subsidized medications. Results: 61% reached target BP vs. usual care, demonstrating real-world impact.

This trial exemplifies Duke-NUS's emphasis on cost-effective, evidence-based solutions, informing CDSS development.

EmPaTHy Programme: Pioneering CDSS at Duke-NUS

The EmPaTHy (Enhancing Primary Care through Translational Health and Implementation Yield) programme under SingHealth Duke-NUS develops the ENHANCe CDSS for HBPM-based hypertension management. It standardizes PCP decisions, pilots integration with electronic records, and evaluates outcomes. Related projects include hypertension phenotyping via ambulatory BP and patient experience studies, fostering interdisciplinary training for Duke-NUS students.

This initiative addresses review gaps, positioning Singapore universities as hubs for digital health innovation.

Technological Innovations and Global Context

Reviewed CDSS examples include Bluetooth-enabled devices auto-uploading to apps/dashboards (e.g., Lv et al., 2017) and telehealth platforms triggering pharmacist reviews (Margolis et al., 2013). While US-dominant (49%), Asian studies from China, Japan, and Singapore highlight adaptability. Duke-NUS research advocates hybrid systems blending rules with machine learning for guideline-aligned recommendations.

Implications for Singapore's Healthcare and Higher Education

With hypertension affecting 1 in 3 adults, CDSS could optimize polyclinic workflows, reduce CVD burden, and cut costs. Duke-NUS's work trains clinician-researchers via PhD/MD-PhD programs, integrating implementation science. For aspiring medical professionals, explore opportunities at higher-ed-jobs or rate faculty via Rate My Professor.

Singapore's Healthier SG initiative aligns, promoting preventive care. Future CDSS must prioritize usability for elderly patients and EMR integration.

Stakeholder Perspectives and Real-World Cases

PCPs value CDSS time-savings but seek training; patients appreciate empowerment but need education. In Singapore, pilot apps like Health Buddy show promise, though adoption lags among seniors. Duke-NUS trials demonstrate 95% medication adherence in interventions vs. 84% usual care.

• Benefits: Better control, fewer visits, equity in access.
• Risks: Data privacy, over-reliance, algorithm biases.

Future Outlook: Bridging Gaps Through Research

Duke-NUS calls for theoretical frameworks (e.g., person-based design), guideline-based algorithms, and hybrid CDSS. Ongoing EmPaTHy pilots and national scalability could transform care. As Singapore invests in digital health, Duke-NUS researchers lead, offering actionable insights for global hypertension control.

Visit Singapore higher ed jobs for med research roles. For career guidance, check higher-ed-career-advice.

Photo by Sreehari Devadas on Unsplash

Conclusion: Empowering Better Hypertension Control

The Duke-NUS-SingHealth review illuminates CDSS potential with HBPM, addressing Singapore's hypertension epidemic. By tackling gaps, these innovations promise enhanced outcomes, training next-gen leaders at Duke-NUS. Explore faculty ratings on Rate My Professor, jobs at Higher Ed Jobs, advice via Career Advice, or post openings at University Jobs and Post a Job.